| Year |
Citation |
Score |
| 2022 |
Amano M, Yedidi RS, Salcedo-Gómez PM, Hayashi H, Hasegawa K, Martyr CD, Ghosh AK, Mitsuya H. Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors . Antimicrobial Agents and Chemotherapy. AAC0171521. PMID 34978889 DOI: 10.1128/AAC.01715-21 |
0.664 |
|
| 2019 |
Amano M, Salcedo-Gómez PM, Yedidi RS, Zhao R, Hayashi H, Hasegawa K, Nakamura T, Martyr CD, Ghosh AK, Mitsuya H. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. Antimicrobial Agents and Chemotherapy. PMID 31061155 DOI: 10.1128/Aac.00466-19 |
0.694 |
|
| 2017 |
Aoki M, Hayashi H, Rao KV, Das D, Higashi-Kuwata N, Bulut H, Aoki-Ogata H, Takamatsu Y, Yedidi RS, Davis DA, Hattori SI, Nishida N, Hasegawa K, Takamune N, Nyalapatla PR, et al. A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. Elife. 6. PMID 29039736 DOI: 10.7554/Elife.28020 |
0.708 |
|
| 2017 |
Amano M, Miguel Salcedo-Gómez P, Yedidi RS, Delino NS, Nakata H, Venkateswara Rao K, Ghosh AK, Mitsuya H. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. Scientific Reports. 7: 12235. PMID 28947797 DOI: 10.1038/S41598-017-12052-9 |
0.734 |
|
| 2017 |
Yedidi RS, Wendler P, Enenkel C. AAA-ATPases in Protein Degradation. Frontiers in Molecular Biosciences. 4: 42. PMID 28676851 DOI: 10.3389/Fmolb.2017.00042 |
0.334 |
|
| 2016 |
Amano M, Salcedo-Gómez PM, Zhao R, Yedidi RS, Das D, Bulut H, Delino NS, Reddy SV, Ghosh AK, Mitsuya H. A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. Antimicrobial Agents and Chemotherapy. PMID 27620483 DOI: 10.1128/Aac.01428-16 |
0.72 |
|
| 2015 |
Aoki M, Hayashi H, Yedidi RS, Martyr CD, Takamatsu Y, Aoki-Ogata H, Nakamura T, Nakata H, Das D, Yamagata Y, Ghosh AK, Mitsuya H. The C5-substituted Tetrahydropyrano-tetrahydofuran-derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs Including Darunavir. Journal of Virology. PMID 26581995 DOI: 10.1128/Jvi.01829-15 |
0.716 |
|
| 2014 |
Yedidi RS, Proteasa G, Martin PD, Liu Z, Vickrey JF, Kovari IA, Kovari LC. A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF. Journal of Molecular Graphics & Modelling. 53: 105-11. PMID 25108107 DOI: 10.1016/J.Jmgm.2014.06.010 |
0.791 |
|
| 2014 |
Yedidi RS, Garimella H, Aoki M, Aoki-Ogata H, Desai DV, Chang SB, Davis DA, Fyvie WS, Kaufman JD, Smith DW, Das D, Wingfield PT, Maeda K, Ghosh AK, Mitsuya H. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. Antimicrobial Agents and Chemotherapy. 58: 3679-88. PMID 24752271 DOI: 10.1128/Aac.00107-14 |
0.606 |
|
| 2014 |
Yedidi RS, Liu Z, Kovari IA, Woster PM, Kovari LC. P1 and P1′ para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: Structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease Journal of Molecular Graphics and Modelling. 47: 18-24. PMID 24291501 DOI: 10.1016/J.Jmgm.2013.10.010 |
0.815 |
|
| 2013 |
Yedidi RS, Muhuhi JM, Liu Z, Bencze KZ, Koupparis K, O'Connor CE, Kovari IA, Spaller MR, Kovari LC. Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease. Biochemical and Biophysical Research Communications. 438: 703-8. PMID 23921229 DOI: 10.1016/J.Bbrc.2013.07.117 |
0.806 |
|
| 2013 |
Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety. Antimicrobial Agents and Chemotherapy. 57: 4920-7. PMID 23877703 DOI: 10.1128/Aac.00868-13 |
0.559 |
|
| 2013 |
Liu Z, Yedidi RS, Wang Y, Dewdney TG, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC. Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance. Biochemical and Biophysical Research Communications. 437: 199-204. PMID 23792096 DOI: 10.1016/J.Bbrc.2013.06.027 |
0.782 |
|
| 2013 |
Liu Z, Yedidi RS, Wang Y, Dewdney TG, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex. Biochemical and Biophysical Research Communications. 431: 232-8. PMID 23313846 DOI: 10.1016/J.Bbrc.2012.12.127 |
0.801 |
|
| 2013 |
Liu Z, Wang Y, Yedidi RS, Dewdney TG, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC. Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes. Biochemical and Biophysical Research Communications. 430: 1022-7. PMID 23261453 DOI: 10.1016/J.Bbrc.2012.12.045 |
0.799 |
|
| 2012 |
Yedidi RS, Liu Z, Wang Y, Brunzelle JS, Kovari IA, Woster PM, Kovari LC, Gupta D. Crystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compounds Biochemical and Biophysical Research Communications. 421: 413-417. PMID 22469467 DOI: 10.1016/J.Bbrc.2012.03.096 |
0.818 |
|
| 2012 |
Liu Z, Wang Y, Yedidi RS, Brunzelle JS, Kovari IA, Sohi J, Kamholz J, Kovari LC. Crystal structure of the extracellular domain of human myelin protein zero. Proteins. 80: 307-13. PMID 21971831 DOI: 10.1002/Prot.23164 |
0.648 |
|
| 2011 |
Yedidi RS, Proteasa G, Martinez JL, Vickrey JF, Martin PD, Wawrzak Z, Liu Z, Kovari IA, Kovari LC. Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variants. Acta Crystallographica. Section D, Biological Crystallography. 67: 524-32. PMID 21636892 DOI: 10.1107/S0907444911011541 |
0.789 |
|
| 2011 |
Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrobial Agents and Chemotherapy. 55: 1717-27. PMID 21282450 DOI: 10.1128/Aac.01540-10 |
0.715 |
|
| 2010 |
Gupta D, Yedidi RS, Varghese S, Kovari LC, Woster PM. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents Journal of Medicinal Chemistry. 53: 4234-4247. PMID 20438064 DOI: 10.1021/Jm100233B |
0.656 |
|
| Show low-probability matches. |